Market Cap | 158.57M | P/E | - | EPS this Y | 12.10% | Ern Qtrly Grth | - |
Income | -98.57M | Forward P/E | -1.62 | EPS next Y | 14.60% | 50D Avg Chg | -13.00% |
Sales | 7M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -55.00% |
Dividend | N/A | Price/Book | 0.61 | EPS next 5Y | - | 52W High Chg | -80.00% |
Recommedations | 2.30 | Quick Ratio | 9.48 | Shares Outstanding | 72.96M | 52W Low Chg | 3.00% |
Insider Own | 14.80% | ROA | -28.07% | Shares Float | 52.64M | Beta | 0.20 |
Inst Own | 54.08% | ROE | -51.48% | Shares Shorted/Prior | 865.63K/853.64K | Price | 2.19 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 763,098 | Target Price | 4.00 |
Oper. Margin | -1,422.01% | Earnings Date | Nov 13 | Volume | 168,867 | Change | 0.00% |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
HC Wainwright & Co. | Neutral | Oct 2, 24 |
HC Wainwright & Co. | Buy | Aug 14, 24 |
HC Wainwright & Co. | Buy | Jul 22, 24 |
HC Wainwright & Co. | Buy | May 10, 24 |
HC Wainwright & Co. | Buy | Mar 15, 24 |
HC Wainwright & Co. | Buy | Dec 4, 23 |
HC Wainwright & Co. | Buy | Nov 27, 23 |
Wells Fargo | Equal-Weight | Nov 14, 23 |
HC Wainwright & Co. | Buy | Oct 12, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Morningside Venture Investment... | 10% Owner 10% Owner | Jan 23 | Sell | 6.9 | 160,000 | 1,104,000 | 5,712,993 | 01/25/23 |
Morningside Venture Investment... | 10% Owner 10% Owner | Jan 17 | Sell | 6.79 | 6,114 | 41,514 | 5,872,993 | 01/19/23 |
Kirk Christopher J. | President and CSO President and CSO | Jun 23 | Option | 0.90 | 33,060 | 29,754 | 381,484 | 06/27/22 |